Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS
Contenuto archiviato il 2024-05-29

Tiam1-Rac signalling in lymphomagenesis

Obiettivo

Background: Retrovirus-induced tumours acquire in time increasing numbers of proviruses in their genome, which are required for the activation of additional (onco)-genes that contribute to tumour progression.

Insertional mutagenesis in oncogene-bearing transgenic mice is therefore a powerful strategy to identify genes that cooperate with the transgene in the formation and progression of tumours.

In the host lab, the Tiam1 gene was identified by retroviral insertional mutagenesis in combination with selection for invasive T-lymphoma cells. The Tiam1 gene was also frequently activated (>70%) in T-lymphomas induced by retroviral infection of tumour-prone transgenic Em-Pim1 mice.

Tiam1 thus seems to play a critical role in the initiation and progression of T-lymphomas. Tiam1 encodes an activator of the Rho-like GTPase Rac. Rho-GTPases regulate a wide variety of cellular processes including cytoskeletal rearrangements, cell migration, and gene transcription.

Objectives: In this proposal we want to uncover the signalling pathways that act downstream or parallel of Tiam1and that are essential for lymphomagenesis in vivo. To this end, we propose to perform an insertional mutagenesis screen on tumour-prone transgenic Eµ-Pim1 mice in a Tiam1-deficient background.

Strategy: T-lymphomas will be induced in Tiam1-deficient Eµ-Pim1 mice by Moloney Murine Leukemia virus (M-MuLV) infection. Targeted genes will be identified using improved Splinkerette PCR. The sequence data will be mapped and used to identify common insertion sites. The involvement of the gene targets in lymphomagenesis will be confirmed by in vitro and in vivo analyses.

Results: The obtained results are expected to give insight into the downstream signalling pathways of Tiam that are acting in the development and progression of lymphomas in vivo. These gene products may turn out to be targets for the development of diagnostic tools or novel anti-cancer therapies.

Campo scientifico (EuroSciVoc)

Parole chiave

Argomento(i)

Invito a presentare proposte

FP6-2002-MOBILITY-5
Vedi altri progetti per questo bando

Meccanismo di finanziamento

EIF - Marie Curie actions-Intra-European Fellowships

Coordinatore

THE NETHERLANDS CANCER INSTITUTE DIVISION OF CELL BIOLOGY
Contributo UE
Nessun dato
Indirizzo


Paesi Bassi
Costo totale
Nessun dato